Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunogenic polypeptide surface layer-expressing bifidobacterium

An immunogenic peptide, bifidobacteria technology, applied in the direction of peptide sources, bacteria, bacterial peptides, etc., can solve the problems of large side effects and long treatment period

Inactive Publication Date: 2015-11-18
KOBE UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the combination therapy of pegylated interferon α and antiviral drug ribavirin has a type 1 virus elimination rate of less than 50%, and the treatment period is long and side effects are large. Therefore, more effective therapeutic drugs are required. development and establishment of therapeutics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic polypeptide surface layer-expressing bifidobacterium
  • Immunogenic polypeptide surface layer-expressing bifidobacterium
  • Immunogenic polypeptide surface layer-expressing bifidobacterium

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0147] (preparation of transformed bifidobacteria)

[0148] Hereinafter, an example of the preparation procedure of a transformed bifidobacterium in which an immunogenic polypeptide of interest is expressed and presented as a fusion protein on the surface of bifidobacteria will be described.

[0149] 1. Acquisition of genes

[0150] The gene encoding GLBP and the gene encoding the immunogenic polypeptide of interest can be obtained based on known gene sequence or amino acid sequence information, respectively. For example, using genomic DNA or cDNA prepared from any bifidobacterium as a template, using a primer pair prepared based on the sequence information of the GLBP structural gene of the bifidobacterium, amplified by polymerase chain reaction (PCR) to obtain . Generally, since multiple codons exist for one amino acid, a gene may have a base sequence different from a known base sequence or a base sequence based on a known amino acid sequence.

[0151] For example, the ge...

Embodiment 1

[0201] (Example 1: Design of HCVNS3 polypeptide gene for bifidobacterium surface layer expression)

[0202] design figure 2 The two amino acid sequences shown are based on the NS3 linker site (1196-1215 positions) of the HCV-1b type polypeptide and the β-α-β structural domain (1216-1350 positions) on the upstream side, which will be derived from the NS3 Antigenic peptides are linked to the N-terminus and C-terminus of the base domain.

[0203] Amino acid sequence 1( figure 2 >1: SEQ ID NO: 23) The N-terminal side of the basic domain is connected to a region containing QSFLATCINGVCWTVYHGAG (1067-1086, CD8 epitope 1: SEQ ID NO: 4), and the C-terminal side is connected to EIPFYGKAI (1372 ~1380 position, CD8 epi position 4: sequence number 7), KLSALGVNA (position 1406~1414, CD8 epi position 6: sequence number 9) and VATDALMTGYTGDFDSVIDC (position 1435~1454, CD8 epi position 7: sequence number 10) area.

[0204] Amino acid sequence 2( figure 2 >2: SEQ ID NO: 24) A region co...

Embodiment 2

[0206] (Example 2: Preparation of NS3 Protein Surface Expression Transformed Bifidobacteria)

[0207] Based on the amino acid sequences 1 and 2 (sequence numbers 23 and 24, respectively) designed in Example 1, a gene sequence conforming to the codon usage frequency (http: / / www.kazusa.or.jp / codon / ) of bifidobacteria was designed 1 and 2 (sequence numbers 25 and 27 respectively; corresponding amino acid sequences are represented by sequence numbers 26 and 28), based on these gene sequence information, full-length synthesis of respective gene fragments (the former is also referred to as "long form", the The latter is called "short form"). The full-length synthesis of the gene fragments was entrusted to GenScript Corporation. The obtained gene fragment was treated with XhoI and SalI, and inserted into recombinant plasmid pJT101 treated with XhoI and SalI (Patent Document 4 and Non-Patent Document 4). Plasmid pJT101 contains the GLBP gene derived from Bifidobacterium longum JCM12...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A bifidobacterium-expressing gene for expressing an immunogenic polypeptide on the surface of bifidobacterium. The gene includes a gene that codes immunogenic polypeptides. The immunogenic polypeptides include a prescribed base domain and at least one antigen peptide. The at least one antigen peptide is linked to either the N-terminal side or the C-terminal side of the base domain. This bifidobacterium-expressing gene can also include a gene that codes a bifidobacterium-derived GNB / LNB substrate-binding protein.

Description

technical field [0001] The present invention relates to immunogenic polypeptides expressing bifidobacteria on the surface, and in more detail, for example, to immunogenic polypeptides expressing bifidobacteria on the surface of immunogenic polypeptides capable of producing hepatitis C vaccine compositions. Background technique [0002] There are more than 170 million carriers of hepatitis C virus (HCV) in the world, and about 70% are exposed to the risk of developing chronic hepatitis, liver cirrhosis, and liver cancer. There are also about 2 million carriers in Japan, about 80% of whom are infected with type 1b. [0003] As a treatment for hepatitis C, interferon therapy is mainly performed. However, the combination therapy of pegylated interferon α and antiviral drug ribavirin has a type 1 virus elimination rate of less than 50%, and the treatment period is long and side effects are large. Therefore, more effective therapeutic drugs are required. development and establis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K35/74A61K39/00A61K39/29A61K48/00A61P31/14A61P37/04C12N1/21
CPCA61K39/12A61K35/745A61K39/29A61K2039/523A61K2039/542A61K2039/585C07K14/195A61P31/14A61P37/04C12N2770/24234A61K39/05C12N7/00
Inventor 白川利朗堀田博片山高岭
Owner KOBE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com